Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus
Overview
Chemistry
Molecular Biology
Affiliations
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter, playing a central role in the regulation of cortical excitability and the maintenance of the excitatory/inhibitory (E/I) balance. Several lines of evidence point to a remodeling of the cerebral GABAergic system in Alzheimer's disease (AD), with past studies demonstrating alterations in GABA receptor and transporter expression, GABA synthesizing enzyme activity and focal GABA concentrations in post-mortem tissue. AD is a chronic neurodegenerative disorder with a poorly understood etiology and the temporal cortex is one of the earliest regions in the brain to be affected by AD neurodegeneration. Utilizing NanoString nCounter analysis, we demonstrate here the transcriptional downregulation of several GABA signaling components in the post-mortem human middle temporal gyrus (MTG) in AD, including the GABA receptor α, α, α, α, β, β, β, δ, γ, γ, and θ subunits and the GABA receptor 2 (GABAR2) subunit. In addition to this, we note the transcriptional upregulation of the betaine-GABA transporter (BGT1) and GABA transporter 2 (GAT2), and the downregulation of the 67 kDa isoform of glutamate decarboxylase (GAD), the primary GABA synthesizing enzyme. The functional consequences of these changes require further investigation, but such alterations may underlie disruptions to the E/I balance that are believed to contribute to cognitive decline in AD.
Tripathi S, Kaushik M, Dwivedi R, Tiwari P, Tripathi M, Dada R J Alzheimers Dis Rep. 2025; 8(1):1422-1433.
PMID: 40034358 PMC: 11863739. DOI: 10.1177/25424823241289039.
Identification of early Alzheimer's disease subclass and signature genes based on PANoptosis genes.
Wang W, Lu J, Pan N, Zhang H, Dai J, Li J Front Immunol. 2024; 15:1462003.
PMID: 39650656 PMC: 11621049. DOI: 10.3389/fimmu.2024.1462003.
Exosomal mRNA Signatures as Predictive Biomarkers for Risk and Age of Onset in Alzheimer's Disease.
Bolivar D, Mosquera-Heredia M, Vidal O, Barcelo E, Allegri R, Morales L Int J Mol Sci. 2024; 25(22).
PMID: 39596356 PMC: 11594294. DOI: 10.3390/ijms252212293.
Brain-targeting liposome-based gene delivery exacerbates soluble amyloid-β accumulation in mice.
Wang N, Parsons T, Ren Y, Pan Y, Kurti A, Starling S Heliyon. 2024; 10(20):e39607.
PMID: 39506961 PMC: 11538761. DOI: 10.1016/j.heliyon.2024.e39607.
Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?.
Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J Front Pharmacol. 2024; 15:1459655.
PMID: 39355779 PMC: 11442227. DOI: 10.3389/fphar.2024.1459655.